跳至主要内容
临床试验/NCT00452894
NCT00452894已完成1 期

A Pharmacokinetic, Toleration And Safety Study Of Single And Multiple Oral Doses Of Varenicline In Chinese Healthy Volunteers

Pfizer1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2007年3月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
14
试验地点
1
主要终点
The PK parameters after a single dose and PK parameters after 7 days of multiple dosing respectively.

研究概览

简要总结

This study is to measure how much of varenicline tartrate is in Chinese healthy smokers' blood and urine after taking a single dose and several doses respectively, and also to test the safety (the impact of the study drug on Chinese healthy smokers' body) of varenicline.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male and/or female Chinese subjects between the ages of 18 and 45 years, inclusive.
  • Body Mass Index (BMI) of approximately 19 to 24 kg/m2; and a total body weight ≥50 kg.
  • Individuals who have smoked an average of at least 10 cigarettes per day during the past year, with no period of abstinence greater than 3 months in the past year.

排除标准

  • Heart rate>100 bpm, QRS Interval>120 msec, QTc Interval >430 msec, PR Interval>220 msec, or any other abnormalities observed on the Electrocardiogram.
  • Subjects with a sitting blood pressure of 140/90 mmHg or above at screening.
  • Subjects with evidence or history of clinically significant allergic, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric or neurological disease, or any condition possibly affecting drug absorption.

结局指标

主要结局

The PK parameters after a single dose and PK parameters after 7 days of multiple dosing respectively.

次要结局

  • To gather safety data from Day 0 to Day 17 of the study.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验